Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1
Corporate Governance Report 2025/07/09
Takeda Completes Disposal of Treasury Shares under the LTIP for Company Group Employees Outside of Japan with Partial Forfeiture
2025 ANNUAL INTEGRATED REPORT
Annual Securities Report From April 1, 2024 to March 31, 2025 (The 148th Fiscal Year)
Takeda Announces New Assignments of Directors
Notice Concerning Disposal of Treasury Shares under the Long-Term Incentive Plan for Company Group Employees Outside of Japan
Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan
Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide
Continuation of the Stock Compensation Plan for Directors and the Stock Grant System for Company Management in Japan in 2025
Earnings Report (Kessan Tanshin) for the Fiscal Year Ended March 31, 2025 (IFRS, Consolidated)
Takeda Announces Completion of Acquisition of Own Shares
Takeda Provides Update on Status of Acquisition of Own Shares
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
Takeda Provides Update on Status of Acquisition of Own Shares
Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026
Takeda Provides Update on Soticlestat (TAK-935)
Takeda Announces Acquisition of Own Shares
Notice of the Revised Forecast of Consolidated Financials for FY2024 (IFRS)